Sentence examples for opportunity trials from inspiring English sources

Window of opportunity trials have been extensively applied to breast cancer.

Among the alternative trial designs, presurgical window of opportunity trials envision a short course treatment in the time window between diagnostic biopsy and surgery in a moderately-sized patient population.

However, in selected circumstances, first-line systemic treatment may be more appropriate in order to avoid neurocognitive toxicities, and potential options should be evaluated in window of opportunity trials.

The Clinical Trials Meeting planners focused on discussion of (1) novel trial designs, including window-of opportunity trials and appropriate control groups for randomized trials, (2) targets specific to serous carcinoma and promises and pitfalls of separate trials for women with tumors of this histology (3) specific recommendations for future randomized trials.

Furthermore, several studies have demonstrated that Ki67 expression will increase after CNB, which may be caused by biopsy stimulation, arguing that this Ki67 change needs to be considered in clinical practice as well as in "window of opportunity" trials [ 11, 13].

We conducted a neoadjuvant, single-arm, "window of opportunity" trial to examine the clinical and biological effects of metformin on patients with breast cancer.

This includes a window of opportunity trial by Hadad and colleagues [ 3], where treated patients showed significant upregulation of p-AMPK compared with the control group.

Our recent window of opportunity trial had shown that a 4-week pre-surgical treatment with metformin did not affect proliferative activity overall as measured by Ki67 LI.

Second, the Moving to Opportunity trial in the mid-1990s enroverd over 3,000 families in high-poverty neighborhoods of Baltimore, Maryland Boston, Massachusetts Chicago, Illinois Los Angeles, CalifornianiandaNew York, New Yorkork.

In a recent issue of Breast Cancer Research, Dowling and colleagues [ 10] present their mechanistic studies from a previously reported single arm, neoadjuvant, window of opportunity trial of metformin in non-diabetic breast cancer patients.

Likewise, the decreases in IR expression and p-Akt are consistent with a two arm window of opportunity trial conducted by Bonanni and colleagues [ 4], where non-diabetic women with breast cancer were randomized to metformin or no drug.